

Format for ANSWERING REVIEWERS



Invited mini-review article (ID = 02494908)

Porto, 25 July 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 3937-edited.doc).

Title (Invited mini-review article - ID = 02494908): HER2 therapies and gastric cancer: a step forward

Author: Ramon Andrade de Mello, Andrea Marin Marques, António Araújo

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 3937

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer
Reviewer I (00058121)

Authors have perfectly gone through the current knowledge considering HER2 therapies and gastric cancer. A brief report not just a list of names of other targeted agents might be on readers' interest e.g: In gastric cancer patients, amplification and expression of c-Met often indicates poor prognosis. Several types of targeted agents have been developed for c-Met pathway. I would expect authors to give some future perspectives: The article does not introduce any idea that appears promising or might stimulate others to develop promising alternatives.

REPLY: thank you very much for your comments. We improved our text discussion and also added issues regarding c-MET targeted therapies and others targets. Furthermore, future perspectives were provided in our article. Please see yellow-highlighted in the text.

“...Furthermore, hepatocyte growth factor (HGF) and its receptor, the trans-membrane tyrosine kinase c-MET, promote cell proliferation, survival, motility and invasion as well as morphologic changes that stimulate tissue...” ... In 2013, Shah *et al* ^[27] reported 67 advanced gastric cancer patients who were treated with foretinib irrespective of c-MET status. Best response was stable disease (SD) in 10 (23%) patients receiving...” ... “Nowadays, an interesting biologic option is available, such as trastuzumab, for combination with platinum-5-FU for prolongs OS in a sub-set of patients. However, only 20 % of advanced GC harbor with HER2 overexpression...”

Reviewer II (00504611)

This is an interesting review which describes the state-of-the-art of HER2 therapy in gastric cancer. I have suggested minor changes to the text.

REPLY: thank you very much for your comments. We appreciated all language review suggested and

accepted throughout the text.

3 References and typesetting were corrected and an English review as performed.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in dark ink, appearing to read 'Ramon Andrade de Mello', with a stylized flourish at the end.

Ramon Andrade de Mello, MD, PhD
Department of Medical Oncology
Portuguese Oncology Institute
Rua Dr. António Bernardino de Almeida
4200-072, Porto
Portugal.
Mob.: +351 912040770
Email: ramondemello@gmail.com